CIPLA Financial Statement Analysis
|
||
|
The Revenues of CIPLA have increased by 13.59% YoY .
The Earnings Per Share (EPS) of CIPLA has increased by 11.29 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
CIPLA Last 5 Annual Financial Results
[BOM: 500087|NSE : CIPLA]
| Consolidated | Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 |
|---|---|---|---|---|---|
| Revenues | ₹21,763 Cr | ₹19,160 Cr | ₹17,132 Cr | ₹16,362 Cr | ₹15,156 Cr |
| Expenses | ₹17,251 Cr | ₹14,911 Cr | ₹13,951 Cr | ₹13,265 Cr | ₹12,329 Cr |
| Operating Profit (Excl OI) | ₹4,512 Cr | ₹4,249 Cr | ₹3,181 Cr | ₹3,097 Cr | ₹2,826 Cr |
| Other Income | ₹322 Cr | ₹270 Cr | ₹369 Cr | ₹477 Cr | ₹358 Cr |
| Interest | ₹106 Cr | ₹161 Cr | ₹197 Cr | ₹168 Cr | ₹114 Cr |
| Depreciation | ₹1,052 Cr | ₹1,068 Cr | ₹1,175 Cr | ₹1,326 Cr | ₹1,323 Cr |
| Profit Before Tax | ₹3,493 Cr | ₹3,290 Cr | ₹2,178 Cr | ₹2,079 Cr | ₹1,669 Cr |
| Profit After Tax | ₹2,559 Cr | ₹2,401 Cr | ₹1,547 Cr | ₹1,510 Cr | ₹1,419 Cr |
| Consolidated Net Profit | ₹2,517 Cr | ₹2,405 Cr | ₹1,547 Cr | ₹1,528 Cr | ₹1,411 Cr |
| Earnings Per Share (Rs) | ₹34.71 | ₹31.19 | ₹29.82 | ₹19.18 | ₹18.96 |
| PAT Margin (%) | 9.17 | 8.61 | 8.51 | 5.70 | 6.31 |
| ROE(%) | 12.85 | 13.10 | 14.13 | 10.09 | 10.37 |
| ROCE(%) | 18.19 | 17.24 | 17.85 | 12.53 | 11.94 |
| Total Debt/Equity(x) | 0.02 | 0.04 | 0.10 | 0.18 | 0.29 |
Key Financials |
||
| Market Cap | : | ₹ 113,795.0 Cr |
| Revenue (TTM) | : | ₹ 25,350.2 Cr |
| Net Profit(TTM) | : | ₹ 3,744.0 Cr |
| EPS (TTM) | : | ₹ 46.4 |
| P/E (TTM) | : | 30.4 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| CIPLA | 4.1% | -4.8% | 55.6% |
| SUN PHARMACEUTICAL INDUSTRIES | -2.3% | -6.5% | 55.3% |
| DR REDDYS LABORATORIES | 4% | 0.8% | 29.4% |
| ZYDUS LIFESCIENCES | -1.2% | -5.2% | 83.9% |
| DIVIS LABORATORIES | 7.8% | 17.4% | 20.3% |
| MANKIND PHARMA | 1.3% | 7% | NA |
| TORRENT PHARMACEUTICALS | 3.9% | 5.1% | 66.1% |
| LUPIN | 0.6% | 0.5% | 127.2% |
| AUROBINDO PHARMA | 5.1% | 10.9% | 87.1% |
CIPLA Revenues
[BOM: 500087|NSE : CIPLA]
| Y-o-Y | 13.59 % |
| 5 Yr CAGR | 9.47 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2023 | ₹21,763 Cr | 13.59 | |
| Mar2022 | ₹19,160 Cr | 11.84 | |
| Mar2021 | ₹17,132 Cr | 4.70 | |
| Mar2020 | ₹16,362 Cr | 7.96 | |
| Mar2019 | ₹15,156 Cr | - | |
CIPLA Operating Profit
[BOM: 500087|NSE : CIPLA]
| Y-o-Y | 6.20 % |
| 5 Yr CAGR | 12.40 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2023 | ₹4,512 Cr | 6.20 | |
| Mar2022 | ₹4,249 Cr | 33.57 | |
| Mar2021 | ₹3,181 Cr | 2.70 | |
| Mar2020 | ₹3,097 Cr | 9.59 | |
| Mar2019 | ₹2,826 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | -6.54 % |
| 5 Yr CAGR | 2.68 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2023 | 20.73% | -6.54 | |
| Mar2022 | 22.18% | 19.44 | |
| Mar2021 | 18.57% | -1.90 | |
| Mar2020 | 18.93% | 1.50 | |
| Mar2019 | 18.65% | - | |
CIPLA Profit After Tax
[BOM: 500087|NSE : CIPLA]
| Y-o-Y | 4.65 % |
| 5 Yr CAGR | 15.58 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2023 | ₹2,517 Cr | 4.65 | |
| Mar2022 | ₹2,405 Cr | 55.50 | |
| Mar2021 | ₹1,547 Cr | 1.23 | |
| Mar2020 | ₹1,528 Cr | 8.31 | |
| Mar2019 | ₹1,411 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | 6.50 % |
| 5 Yr CAGR | 9.80 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2023 | 9.17 % | 6.50 | |
| Mar2022 | 8.61 % | 1.18 | |
| Mar2021 | 8.51 % | 49.30 | |
| Mar2020 | 5.7 % | -9.67 | |
| Mar2019 | 6.31 % | - | |
CIPLA Earnings Per Share (EPS)
[BOM: 500087|NSE : CIPLA]
| Y-o-Y | 11.29 % |
| 5 Yr CAGR | 16.32 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2023 | ₹35 | 11.29 | |
| Mar2022 | ₹31 | 4.59 | |
| Mar2021 | ₹30 | 55.47 | |
| Mar2020 | ₹19 | 1.16 | |
| Mar2019 | ₹19 | - | |
CIPLA Return on Capital Employed (ROCE)
[BOM: 500087|NSE : CIPLA]
| Y-o-Y | 5.51 % |
| 5 Yr CAGR | 11.10 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2023 | 18.19% | 5.51 | |
| Mar2022 | 17.24% | -3.42 | |
| Mar2021 | 17.85% | 42.46 | |
| Mar2020 | 12.53% | 4.94 | |
| Mar2019 | 11.94% | - | |
CIPLA Share Price vs Sensex
| Current Share Price | : | ₹1,409.4 |
| Current MarketCap | : | ₹ 113,795.0 Cr |
| Updated EOD on | : | Apr 26,2024 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| CIPLA | 4.1% |
-4.8% |
55.6% |
| SENSEX | 0.9% |
1.5% |
23.6% |
CIPLA related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| S&P BSE HEALTHCARE | 3% | 4% | 55.2% |
| S&P BSE DIVIDEND STABILITY | 2.9% | 4.3% | 58.7% |
| S&P BSE ALLCAP | 2.3% | 5% | 41.4% |
| MFG | 2.1% | 3.8% | 44% |
| S&P BSE 500 | 2.1% | 4.5% | 39.2% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY HEALTHCARE | 3.2% | 2.5% | 51.3% |
| NIFTY PHARMA | 3.2% | 2.2% | 51.4% |
| NIFTY 100 ALPHA 30 | 3% | 9% | 71.5% |
| NIFTY500 MULTICAP 50:25:25 | 2.8% | 6.7% | 49.4% |
| NIFTY LARGE MIDCAP 250 | 2.7% | 5.5% | 46.4% |
You may also like the below Video Courses
FAQ about CIPLA Financials
How the annual revenues of CIPLA have changed ?
The Revenues of CIPLA have increased by 13.59% YoY .
How the Earnings per Share (EPS) of CIPLA have changed?
The Earnings Per Share (EPS) of CIPLA has increased by 11.29 % YoY .
Check out Intrinsic Value of Peers of CIPLA
Compare Stock Analytics of Peers of CIPLA
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
